Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | FPR3 | P25089 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESRRA | P11474 | 1/20 | 0.46 |
| ▸ | ESRRG | P62508 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927555 | 1.00 | GPR119 (0.52) | GPR119KCNK3KCNK9RORCFPR2 | |
| SCHEMBL20511076 | 0.87 | GPR119 (0.67) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL27399965 | 0.87 | GPR119 (0.67) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL31288397 | 0.86 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL29723219 | 0.86 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL17135075 | 0.86 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL22523841 | 0.86 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL12005457 | 0.86 | GPR119 (0.52) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL31288417 | 0.86 | HDAC1 (0.55) | GPR119NR1H2ALDH1A1LMNAMAPT | |
| SCHEMBL10111733 | 0.86 | GPR119 (0.67) | GPR119RORCNR1H2USP30PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-11-25 | — | — | US | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-06-25 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4255906-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2023-02-23 | — | — | US | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022117487-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | GPR119 119/4885KCNK3 390/4885KCNK9 1092/4885 |
| US-12018029-B2 | Hexahydropyrrolo[3,4-c]pyrrole derivatives useful as LOX inhibitors | LOX, LOXL1, LOXL3 | GPR119 2107/4885KCNK3 3300/4885KCNK9 4278/4885 |
| US-20230054473-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | EGFR, ERBB2, ERBB3 | GPR119 475/4885KCNK3 1938/4885KCNK9 1896/4885 |
| US-12479849-B2 | EGFR inhibitors for the treatment of cancer | EGFR, ERBB2, ERBB3 | GPR119 656/4885KCNK3 1630/4885KCNK9 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.